News

American Association of Individual Investors20m
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%
Design Therapeutics, Inc.’s DSGN share price has dipped by 5.42%, which has investors questioning if this is right time to ...
Pharmabiz9h
UK MHRA grants marketing authorisation to Biogen’s omaveloxolone to treat Friedreich’s ataxia
UK MHRA grants marketing authorisation to Biogen’s omaveloxolone to treat Friedreich’s ataxia: United Kingdom Friday, April 25, 2025, 12:00 Hrs [IST] The Medicines and Healthc ...
NC Biotech1d
Epigenos Biosciences brings epigenetic precision to gene therapy
Hathway’s technology uses natural epigenetic processes to dial gene activity up or down, rather than rewriting the genetic ...
PMLive1d
Biogen’s Skyclarys granted MHRA approval for rare movement disorder Friedreich’s ataxia
Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...
The Pharma Letter1d
MHRA approves first UK treatment for Friedreich’s ataxia
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...
Biogen’s Friedreich’s ataxia treatment authorised in UK
Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...
Local woman with rare disease spearheading effort to educate more people about handicapped parking spots
A local woman with a rare disease is leading an effort to draw awareness to an issue that’s important to her and others who ...
Mirage News2d
MHRA Greenlights UKs First Friedreichs Ataxia Drug
As with all products, we will keep its safety under close review. The Medicines and Healthcare products Regulatory Agency ...